丁罗环酮门诊治疗哮喘合并重度抑郁障碍的疗效研究
2007/11/02
哮喘患者常合并抑郁障碍，但目前对于哮喘合并抑郁障碍抗抑郁治疗的临床研究尚不充分。作者研究了丁罗环酮门诊治疗对18例哮喘合并重度抑郁障碍患者焦虑、抑郁评分的影响。
结果显示：丁罗环酮门诊治疗12周，能显著降低哮喘患者的汉密尔顿焦虑评分以及汉密尔顿抑郁评分，并且哮喘症状控制问卷评分的改善与患者汉密尔顿抑郁评分以及抑郁症状评分的改善显著相关。
由此可见，丁罗环酮能显著减轻哮喘患者所合并得焦虑、抑郁障碍，哮喘症状控制的改善与抑郁障碍的减轻有关。
（蔡闯 广州医学院第一附属医院 广州呼吸病研究所 510120 摘译）
（Int J Psychiatry Med. 2007;37:23-28）
Bupropion in the treatment of outpatients with asthma and major depressive disorder.
Brown ES, Vornik LA, Khan DA, Rush AJ.
Objective Depressive disorders are common in asthma. Despite the high prevalence, antidepressant therapy in asthma patients with depression remains under-investigated. The objective of this pilot study was to investigate the use of bupropion for depression and anxiety in depressed asthma patients.
Method：We conducted a 12-week open-label study of bupropion in 18 depressed asthma patients. Participants were assessed with the Hamilton Rating Scale for Depression (HAM-D-17), Hamilton Rating Scale for Anxiety (HAM-A), Inventory of Depressive Symptomatology—Self-Report (IDS-SR), Asthma Control Questionnaire (ACQ) and spirometry at baseline and weeks 1, 2, 4, 8, and 12.
Results：Significant baseline to exit improvements were observed on the HAM-D-17 (mean change = 4.72, SD = 7.78, p = 0.02) and the HAM-A (mean change = 2.12, SD = 3.97, p = 0.04). Based on the HAM-D-17 scores, 27.8% of the patients were responders and 16.7% were remitters. Significant correlations were found between changes in ACQ score and HAM-D-17 r = 0.73, p = 0.001), ACQ score and IDS-SR r = 0.58, p = 0.012), and FEV1% Predicted and HAM-D-17 r = –0.66, p = 0.006).
Conclusions： Bupropion treatment was associated with significant improvements in depression and anxiety symptoms in asthma patients. Improvements in asthma correlated significantly with improvements in depression.
Keywords： asthma; bupropion; major depressive disorder
上一篇：
2-tone练习器----有助患者正确使用定量吸入器用药
下一篇：
没有了
